Creating a high-resolution picture of Cygnus with the Cherenkov Telescope Array

The Cygnus region hosts one of the most remarkable star-forming regions in the Milky Way. Indeed, the total mass in molecular gas of the Cygnus X complex exceeds 10 times the total mass of all other nearby star-forming regions. Surveys at all wavelengths, from radio to gamma-rays, reveal that Cygnus contains such a wealth and variety of sources---supernova remnants (SNRs), pulsars, pulsar wind nebulae (PWNe), H II regions, Wolf-Rayet binaries, OB associations, microquasars, dense molecular clouds and superbubbles---as to practically be a galaxy in microcosm. The gamma-ray observations along reveal a wealth of intriguing sources at energies between 1 GeV and tens of TeV. However, a complete understanding of the physical phenomena producing this gamma-ray emission first requires us to disentangle overlapping sources and reconcile discordant pictures at different energies. This task is made more challenging by the limited angular resolution of instruments such as the Fermi Large Area Telescope, ARGO-YBJ, and HAWC and the limited sensitivity and field of view of current imaging atmospheric Cherenkov telescopes (IACTs). The Cherenkov Telescope Array (CTA), with its improved angular resolution, large field of view, and order of magnitude gain in sensitivity over current IACTs, has the potential to finally create a coherent and well-resolved picture of the Cygnus region between a few tens of GeV and a hundred TeV. We describe a proposed strategy to study the Cygnus region using CTA data, which combines a survey of the whole region at $65^\circ < l < 85^\circ$ and $-3.5^\circ < b < 3.5^\circ$ with deeper observations of two sub-regions that host rich groups of known gamma-ray sources

The On-Site Analysis of the Cherenkov Telescope Array

The Cherenkov Telescope Array (CTA) observatory will be one of the largest ground-based very high-energy gamma-ray observatories. The On-Site Analysis will be the first CTA scientific analysis of data acquired from the array of telescopes, in both northern and southern sites. The On-Site Analysis will have two pipelines: the Level-A pipeline (also known as Real-Time Analysis, RTA) and the level-B one. The RTA performs data quality monitoring and must be able to issue automated alerts on variable and transient astrophysical sources within 30 seconds from the last acquired Cherenkov event that contributes to the alert, with a sensitivity not worse than the one achieved by the final pipeline by more than a factor of 3. The Level-B Analysis has a better sensitivity (not be worse than the final one by a factor of 2) and the results should be available within 10 hours from the acquisition of the data: for this reason this analysis could be performed at the end of an observation or next morning. The latency (in particular for the RTA) and the sensitivity requirements are challenging because of the large data rate, a few GByte/s. The remote connection to the CTA candidate site with a rather limited network bandwidth makes the issue of the exported data size extremely critical and prevents any kind of processing in real-time of the data outside the site of the telescopes. For these reasons the analysis will be performed on-site with infrastructures co-located with the telescopes, with limited electrical power availability and with a reduced possibility of human intervention. This means, for example, that the on-site hardware infrastructure should have low-power consumption. A substantial effort towards the optimization of high-throughput computing service is envisioned to provide hardware and software solutions with high-throughput, low-power consumption at a low-cost.Comment: In Proceedings of the 34th International Cosmic Ray Conference (ICRC2015), The Hague, The Netherlands. All CTA contributions at arXiv:1508.0589

Two susceptibility loci identified for prostate cancer aggressiveness

Most men diagnosed with prostate cancer will experience indolent disease; hence, discovering genetic variants that distinguish aggressive from nonaggressive prostate cancer is of critical clinical importance for disease prevention and treatment. In a multistage, case-only genome-wide association study of 12,518 prostate cancer cases, we identify two loci associated with Gleason score, a pathological measure of disease aggressiveness: rs35148638 at 5q14.3 (RASA1, P = 6.49 x 10^-9) and rs78943174 at 3q26.31 (NAALADL2, P = 4.18 x 10^-8). In a stratified case–control analysis, the SNP at 5q14.3 appears specific for aggressive prostate cancer (P = 8.85 x 10^-5) with no association for nonaggressive prostate cancer compared with controls (P = 0.57). The proximity of these loci to genes involved in vascular disease suggests potential biological mechanisms worthy of further investigation

Genome-Wide Association Study of Prostate Cancer-Specific Survival

Background: Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical. Methods: We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR). Results: We observed no significant association between genetic variants and prostate cancer survival. Conclusions: Common genetic variants with large impact on prostate cancer survival were not observed in this study. Impact: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes. (C) 2015 AACR

A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

When the COVID-19 pandemic began, formal frameworks to collect data about affected patients were lacking. The COVID-19 and Cancer Consortium (CCC19) was formed to collect granular data on patients with cancer and COVID-19 at scale and as rapidly as possible. CCC19 has grown from five initial institutions to 125 institutions with >400 collaborators. More than 5,000 cases with complete baseline data have been accrued. Future directions include increased electronic health record integration for direct data ingestion, expansion to additional domestic and international sites, more intentional patient involvement, and granular analyses of still-unanswered questions related to cancer subtypes and treatments. When the COVID-19 pandemic began, formal frameworks to collect data about affected patients were lacking. The COVID-19 and Cancer Consortium (CCC19) was formed to collect granular data on patients with cancer and COVID-19 at scale and as rapidly as possible. CCC19 has grown from five initial institutions to 125 institutions with >400 collaborators. More than 5,000 cases with complete baseline data have been accrued. Future directions include increased electronic health record integration for direct data ingestion, expansion to additional domestic and international sites, more intentional patient involvement, and granular analyses of still-unanswered questions related to cancer subtypes and treatments